SI-BONE, Inc. Announces American Medical Association's Publication Of New Category I CPT Code For MIS SI Joint Fusion
SAN JOSE, Calif., Sept. 24, 2014 /PRNewswire/ -- SI-BONE, Inc., a medical device company that pioneered the use of the iFuse Implant System,® a minimally invasive surgical (MIS) device indicated for fusion for certain disorders of the sacroiliac (SI) joint, today announced that the American Medical Association's (AMA) Current Procedural Terminology® (CPT) Editorial Panel has published its CPT 2015 Professional EditionManual, which includes a newly created Category I CPT code for minimally invasive surgical (MIS) sacroiliac (SI) joint fusion. The new CPT code, 27279, becomes effective January 1, 2015. The previous CPT code recommended for MIS SI joint fusion by the AMA, CPT code 0334T, will be deleted by the AMA CPT Editorial Panel to coincide with the introduction of the new Category I CPT code.
According to Michael Mydra, Vice President of Health Outcomes & Reimbursement, "publication by the American Medical Association of a new Category I CPT code for the MIS SI joint fusion procedure is a milestone. Specifically, the MIS procedure is now recognized as an accepted standard of care for patients requiring sacroiliac joint fusion for conditions including sacroiliac joint dysfunction that is a direct result of sacroiliac joint disruptions and degenerative sacroiliitis."
SI-BONE, Inc. received original 510(k) clearance in November 2008 from the Food and Drug Administration (FDA) to market its iFuse Implant System. The CE mark for European commercialization was obtained in November 2010.
Clinical publications have identified the SI joint as a pain generator in up to 22% of low back pain patients.1 In addition, the SI joint is a low back pain generator in 43% to 61% of symptomatic post-lumbar fusion, so-called "failed back surgery" patients.2 Initial treatment options for patients with SI joint disorders typically involve non-surgical management and, when non-surgical treatment of the SI joint fails, surgical treatments such as the iFuse may provide an option.
The iFuse Implant System is a minimally invasive surgical option that uses titanium implants coated with a porous, titanium plasma spray (TPS) that acts as an interference surface, designed to help decrease implant motion and provide immediate fixation and allow for biological fixation to support long term fusion. The iFuse System is intended for sacroiliac joint fusion for conditions including SI joint dysfunction that is a direct result of SI joint disruptions and degenerative sacroiliitis. As with all surgical procedures and permanent implants, there are risks and considerations associated with surgery and use of the iFuse Implant.
About SI-BONE, Inc.
SI-BONE, Inc. (San Jose, California) is the leading sacroiliac joint medical device company dedicated to the development of tools and products for diagnosing and treating patients with low back issues related to SI joint disorders. The company has developed, and is manufacturing and marketing, less invasive approaches using implants for the treatment of certain SI joint pathology. SI-BONE has an experienced management team with extensive experience in orthopedic and spine medical devices. SI-BONE and iFuse Implant System are registered trademarks of SI-BONE, Inc. ©2014 SI-BONE, Inc. All Rights Reserved. 8941.092414
1 Bernard TN, Kirkaldy-Willis WH. Recognizing Specific Characteristics of Nonspecific Low Back Pain. Clinical Orthopedics and Related Research. 1987;217:26680.
2 DePalma M, Ketchum JM, Saullo TR. Etiology of Chronic Low Back Pain in Patients Having Undergone Lumbar Fusion. Pain Medicine. 2011;12:732-9.
SOURCE SI-BONE, Inc.